Nanomedecine Award 2017

The 3rd edition of Nanomedicine Award aiming to honor the best international Nanomedicine innovations for 2017 has been launched in April by the European Platform on Nanomedicine (ETPN) and the EU-funded consortium ENATRANS.

The call for applications are open until mid-August 2017. More information here.

The Nanomedicine Award:

  • aims to honor the best international nanomedicine innovations that will revolutionizing the patient’s life (change the way disease are treated or diagnosed, provide new tools for physicians, etc.)
  • is open to companies, academic and private researchers from Europe and beyond
  • two categories for 2017: 1) More Promising Nanomedicine Project, 2) Best Nanomedicine Product/Deal,

The winners will be announced at BIO Europe (Berlin), on the 7th of November 2017.

Elsevier World Tuberculosis Day 2017 free virtual special issue

As part of World Tuberculosis Day (24th March), Elsevier gathered in a free virtual issue on Tuberculosis several top research articles published across the portfolio of Elsevier published journals, selected by their editors and publishers.

You can acces this free virtual issue here until 30th June 2017. 

European Commission: Open consultation on Antimicrobial resistance

The European Commission launched an open Public Consultation on possible activities under a 'Commission Communication on a One Health Action Plan to support Member States in the fights against Antimicrobial Resistance (AMR)'.

The objective of this consultation is to collect the views and input of citizens, administrations, associations and other organisations for the currently ongoing process on proposals for the Commission communication.

Respondents are invited to take part in the consultation by completing the online questionnaire provided. Two questionnaires are available, one for administrations, associations and other organisations available in English and one for citizens available in English and from next week, in all EU languages.

Deadeline to answer the questionnaire: 28 April 2017

More details and questionnaire are accessible here.


PneumoNP Newsletter - March 2017

The latest trimetrial newsletter from PneumoNP is available.

Read here the latest progress of this project.


WHO's list of bacteria for which new antibiotics are urgently needed

WHO published on February 27th for the 1st time a list of antibiotic-resistant "priority pathogens", which includes 12 families of bacteria that pose the greatest threat to human health. The list is divided into three categories according to the urgency of need for new antibiotics: critical, high and medium priority.

The purpose of the list is to encourage governments to implement policies to incentivize basic science and advanced R&D by both publicly funded agencies and the private sector investing in new antibiotic discovery.

Staphylococcus aureus, methicillin-resistant, vancomycin-intermediate and resistant is considered as a "High priority". Tuberculosis was not included in the list because it is targeted by other, dedicated programmes.

More information here.


The NAREB project has received funding from the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement no 604237.